Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$4.77 - $10.67
Next Earnings Date
May 01 2025
Next Earnings Date
May 01 2025
Latest price
Market Cap | $1.11B |
EV | $832.00M |
Shares Outstanding | 137.34M |
Beta | 1.21 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $9.83 |
P/E 2025E | 17.40x |
P/Revenue 2025E | 4.30x |
Revenue | 72.80% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | 16.90% |
EPS | 193.40% |
Operating Cash Flow | - |
Free Cash Flow | 36.60% |
Gross Margin 2025E | 93.50% |
Net Profit Margin 2025E | 25.58% |
ROE 2025E | - |
ROCE 2024 | 1.52% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Aurinia Pharmaceuticals Inc.
AUPH
Sector
Healthcare
Industry
Biotechnology
CEO
Greenleaf, Peter
Employees
130
Website
www.auriniapharma.comIPO Date
2014-09-03
Headquarters
118 Avenue 14315, Suite 140, Edmonton, Alberta, T5L 4S6, Canada
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved